Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990866 | 0.93 | SMN1; SMN2 (0.39) | GRIK1SMN1; SMN2MMP2MMP3MMP1 | |
| SCHEMBL4983416 | 0.86 | GRIK1 (0.44) | GRIK1 | |
| SCHEMBL4986342 | 0.85 | ALOX15 (0.43) | GRIK1 | |
| SCHEMBL4994158 | 0.85 | GRIK1 (0.40) | GRIK1MMP2MMP3MMP1GRIN2D | |
| SCHEMBL4990707 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL4986369 | 0.84 | GRIK1 (0.38) | GRIK1MMP2MMP3GRIN2DGRIN2A | |
| SCHEMBL4983574 | 0.84 | GRIK1 (0.43) | GRIK1SMN1; SMN2 | |
| SCHEMBL4990589 | 0.84 | PNMT (0.40) | GRIK1 | |
| SCHEMBL4992818 | 0.84 | GRIK1 (0.44) | GRIK1 | |
| SCHEMBL4989306 | 0.84 | ANPEP (0.40) | GRIK1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | GRIK1 413/4885SMN1; SMN2 1368/4885MMP2 4647/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | GRIK1 304/4885SMN1; SMN2 1347/4885MMP2 4713/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | GRIK1 415/4885SMN1; SMN2 1393/4885MMP2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.